Rocket Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Rocket Pharmaceuticals has a total shareholder equity of $329.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $393.7M and $63.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$235.66m |
| Equity | US$329.77m |
| Total liabilities | US$63.92m |
| Total assets | US$393.69m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9IP1's short term assets ($241.8M) exceed its short term liabilities ($40.0M).
Long Term Liabilities: 9IP1's short term assets ($241.8M) exceed its long term liabilities ($23.9M).
Debt to Equity History and Analysis
Debt Level: 9IP1 is debt free.
Reducing Debt: 9IP1 has no debt compared to 5 years ago when its debt to equity ratio was 19%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9IP1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 9IP1 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 23.1% each year.